CP
PCVX icon

Caligan Partners’s Vaxcyte PCVX Stock Holding History

Caligan Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127M Buy
2,188,636
+127,917
+6% +$6.95M 5.99% 4
2026
Q1 		$120M Buy
2,060,719
+355,904
+21% +$19.3M 7.97% 4
2025
Q4 		$78.7M Buy
+1,704,815
New +$76.2M 6.48% 6

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners's PCVX Position: Q2 2026 in Review

Caligan Partners increased its Vaxcyte (PCVX) stake by 6.2% in Q2 2026, buying an estimated $6.95M and bringing the position to 2,188,636 shares worth $127M. The position accounts for 5.99% of the portfolio, ranked #4.

Caligan Partners first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Caligan Partners held 2,188,636 shares of Vaxcyte worth $127M as of Q2 2026.
  • Caligan Partners bought 127,917 Vaxcyte shares in Q2 2026, an estimated $6.95M.
  • Vaxcyte made up 5.99% of Caligan Partners's portfolio in Q2 2026, its #4 holding.
  • Caligan Partners first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.